FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000302080> ?p ?o ?g. }

• W2000302080 endingPage "552" @default.
• W2000302080 startingPage "546" @default.
• W2000302080 abstract "No AccessJournal of UrologyInvestigative Urology1 Aug 1999OPTIMISATION OF THE FORMATION AND DISTRIBUTION OF PROTOPORPHYRIN IX IN THE UROTHELIUM: AN IN VITRO APPROACH A. MARTI, N. LANGE, H. VAN DEN BERGH, D. SEDMERA, P. JICHLINSKI, and P. KUCERA A. MARTIA. MARTI More articles by this author , N. LANGEN. LANGE More articles by this author , H. VAN DEN BERGHH. VAN DEN BERGH More articles by this author , D. SEDMERAD. SEDMERA More articles by this author , P. JICHLINSKIP. JICHLINSKI More articles by this author , and P. KUCERAP. KUCERA More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)68625-9AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: To optimize conditions for photodynamic detection (PDD) and photodynamic therapy (PDT) of bladder carcinoma, urothelial accumulation of protoporphyrin IX (PpIX) and conditions leading to cell photodestruction were studied. Materials and Methods: Porcine and human bladder mucosae were superfused with derivatives of 5-aminolevulinic acid (ALA). PpIX accumulation and distribution across the mucosa was studied by microspectrofluorometry. Cell viability and structural integrity were assessed by using vital dyes and microscopy. Results: ALA esters, especially hexyl-ALA, accelerated and regularized urothelial PpIX accumulation and allowed for necrosis upon illumination. Conclusions: hexyl-ALA used at micromolar concentrations is the most efficient PpIX precursor for PDD and PDT. References 1 : Follow-up of patient with superficial transitional cell carcinoma of the bladder: the case for a change in policy. Br. J. Urol.1993; 72: 135. Google Scholar 2 : Biology and management of bladder cancer. N. Engl. J. Med.1990; 322: 1129. Google Scholar 3 : BCG in perspectives: advances in the treatment of superficial bladder cancer. Eur. Urol.1995; 27: 2. Google Scholar 4 : Endogenous protoporphyrin IX, a clinical useful photosensitizer for photodynamic therapy. J. Photochem. Photobiol B: Biol.1992; 14: 275. Google Scholar 5 : The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolevulinic acid-treated cells. Brit. J. Cancer1996; 74: 688. Google Scholar 6 : Photodynamic therapy with endogenous protoporphyrin IX; basic principles and present clinical experience. J. Photochem. Photobiol B: Biol.1990; 6: 143. Google Scholar 7 : Detection of early bladder cancer by 5-aminolevulinic acid induced Protoporphyrin fluorescence. J. Urol.1996; 155: 105. Link, Google Scholar 8 : Clinical evaluation of a method for detecting superficial transitional cell carcinoma of the bladder by light induced fluorescence of protoporphyrin IX following topical application of 5-aminolevulinic acid. Preliminary results Lasers Surg. Med.1997; 20: 402. Google Scholar 9 : Intravesical instillation of 5-aminolevulinic acid: the fluorescence metabolite is limited to the urothelial cells. Urology1994; 44: 676. Google Scholar 10 : The theory of photodynamic therapy dosimetry: consequences of photodestruction of sensitizer. Photochem. Photobiol. B: Biol.1987; 46: 97. Google Scholar 11 : Cellular fluorescence of the endogenous photosensitizer protoporphyrin IX following exposure to 5-aminolevulinic acid. Photochem. Photobiol. B: Biol.1995; 62: 887. Google Scholar 12 : Dimethylsulfoxide (DMSO); laboratory and clinical evaluation. JAMA1965; 147: 1350. Google Scholar 13 : Microscopic study of the pig ureteral urothelium. J. Urol1997; 157: 1926. Link, Google Scholar 14 : Ion transport across the early chick embryo: I. electrical measurements, ionic fluxes and regional heterogeneity. J. Membr. Biol.1994; 141: 149. Google Scholar 15 : Prodrugs of 5- aminolevulinic acid for photodynamic therapy. Photochem. Photobiol. B: Biol.1996; 64. Google Scholar 16 : Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Res.1997; 57: 1481. Google Scholar 17 : Cytotoxicity of radiocontrast agents on polarized renal epithelial cell monolayers. Cardiovasc. Res.1996; 33: 655. Google Scholar 18 : How do Ca 2+ and 5-aminolevulinic acid-derived oxyradicals promote injury to isolated mitochondria?. Free Radic. Biol. Med.1995; 19: 381. Google Scholar 19 : Biodistribution of protoporphyrin IX in rat urinary bladder after intravesical instillation of 5-aminolevulinic acid. J. Urol.1996; 155: 1744. Link, Google Scholar 20 : Aminolevulinic acid for photodynamic therapy of bladder carcinoma. Urol. Res.1996; 24: 285. Google Scholar 21 : Biodistribution and phototoxicity of 5-aminolevulinic acid-induced PPIX in an orthotopic rat bladder tumor model. J. Urol.1995; 153: 802. Link, Google Scholar 22 : Competition between photobleaching and fluorescence increase of photosensitizing porphyrin and tetrasulphonated chloroaluminiumphtalocyanine. J. Photochem. Photobiol. B: Biol.1990; 5: 311. Google Scholar 23 : Photo-oxidation and singlet oxygen sensitization by protoporphyrin IX and its photo-oxydation products. Photochem. Photobiol. B: Biol.1982; 36: 401. Google Scholar 24 : Photodetection of early human bladder cancer based on the fluorescence of 5-aminolevulinic acid hexyelester-induced protoporphyrin IX: a pilot study. British J. Canc.1999; . Google Scholar From the Institute of Physiology, Faculty of Medicine, University of Lausanne, the Federal Institute of Technology, and the Service of Urology, University Hospital, Lausanne, SwitzerlandAccepted for publication November 8, 1998.(Kucera) Requests for reprints: Institut de Physiologie, Universite de Lausanne, Rue Bugnon 7, 1005 Lausanne, Switzerland.Supported by grant 17 from the Geneva-Vaud Foundation and the Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany.© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited ByJOCHAM D, WITJES F, WAGNER S, ZEYLEMAKER B, van MOORSELAAR J, GRIMM M, MUSCHTER R, POPKEN G, KöNIG F, KNüCHEL R and KURTH K (2018) IMPROVED DETECTION AND TREATMENT OF BLADDER CANCER USING HEXAMINOLEVULINATE IMAGING: A PROSPECTIVE, PHASE III MULTICENTER STUDYJournal of Urology, VOL. 174, NO. 3, (862-866), Online publication date: 1-Sep-2005.SCHMIDBAUER J, WITJES F, SCHMELLER N, DONAT R, SUSANI M and MARBERGER M (2018) Improved Detection of Urothelial Carcinoma In Situ With Hexaminolevulinate Fluorescence CystoscopyJournal of Urology, VOL. 171, NO. 1, (135-138), Online publication date: 1-Jan-2004.EL KHATIB S, DIDELON J, LEROUX A, BEZDETNAYA L, NOTTER D and D'HALLEWIN M (2018) KINETICS, BIODISTRIBUTION AND THERAPEUTIC EFFICACY OF HEXYLESTER 5-AMINOLEVULINATE INDUCED PHOTODYNAMIC THERAPY IN AN ORTHOTOPIC RAT BLADDER TUMOR MODELJournal of Urology, VOL. 172, NO. 5, (2013-2017), Online publication date: 1-Nov-2004.JICHLINSKI P, GUILLOU L, KARLSEN S, MALMSTRÖM P, JOCHAM D, BRENNHOVD B, JOHANSSON E, GÄRTNER T, LANGE N, van den BERGH H and LEISINGER H (2018) Hexyl Aminolevulinate Fluorescence Cystoscopy: A New Diagnostic Tool for Photodiagnosis of Superficial Bladder Cancer—A multicenter studyJournal of Urology, VOL. 170, NO. 1, (226-229), Online publication date: 1-Jul-2003.MARTI A, JICHLINSKI P, LANGE N, BALLINI J, GUILLOU L, LEISINGER H and KUCERA P (2018) Comparison of Aminolevulinic Acid and Hexylester Aminolevulinate Induced Protoporphyrin IX Distribution in Human Bladder CancerJournal of Urology, VOL. 170, NO. 2, (428-432), Online publication date: 1-Aug-2003.ZAAK D, FRIMBERGER D, STEPP H, WAGNER S, BAUMGARTNER R, SCHNEEDE P, SIEBELS M, KNÜCHEL R, KRIEGMAIR M and HOFSTETTER A (2018) QUANTIFICATION OF 5-AMINOLEVULINIC ACID INDUCED FLUORESCENCE IMPROVES THE SPECIFICITY OF BLADDER CANCER DETECTIONJournal of Urology, VOL. 166, NO. 5, (1665-1669), Online publication date: 1-Nov-2001.SUGASI S, LESBROS Y, BISSON I, ZHANG Y, KUCERA P and FREY P (2018) IN VITRO ENGINEERING OF HUMAN STRATIFIED UROTHELIUM: ANALYSIS OF ITS MORPHOLOGY AND FUNCTIONJournal of Urology, VOL. 164, NO. 3 Part 2, (951-957), Online publication date: 1-Sep-2000. Volume 162Issue 2August 1999Page: 546-552 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.MetricsAuthor Information A. MARTI More articles by this author N. LANGE More articles by this author H. VAN DEN BERGH More articles by this author D. SEDMERA More articles by this author P. JICHLINSKI More articles by this author P. KUCERA More articles by this author Expand All Advertisement PDF DownloadLoading ..." @default.
• W2000302080 created "2016-06-24" @default.
• W2000302080 creator A5008028399 @default.
• W2000302080 creator A5010836672 @default.
• W2000302080 creator A5016349256 @default.
• W2000302080 creator A5039942289 @default.
• W2000302080 creator A5087442210 @default.
• W2000302080 creator A5089127172 @default.
• W2000302080 date "1999-08-01" @default.
• W2000302080 modified "2023-10-18" @default.
• W2000302080 title "OPTIMISATION OF THE FORMATION AND DISTRIBUTION OF PROTOPORPHYRIN IX IN THE UROTHELIUM: AN IN VITRO APPROACH" @default.
• W2000302080 cites W1506108633 @default.
• W2000302080 cites W1970228764 @default.
• W2000302080 cites W1983747031 @default.
• W2000302080 cites W1984907354 @default.
• W2000302080 cites W2020275217 @default.
• W2000302080 cites W2022970459 @default.
• W2000302080 cites W2026553119 @default.
• W2000302080 cites W2047638469 @default.
• W2000302080 cites W2061167293 @default.
• W2000302080 cites W2061913116 @default.
• W2000302080 cites W2068592201 @default.
• W2000302080 cites W2070866978 @default.
• W2000302080 cites W2078640879 @default.
• W2000302080 cites W2091601661 @default.
• W2000302080 cites W2094347660 @default.
• W2000302080 cites W2122620614 @default.
• W2000302080 cites W2150240082 @default.
• W2000302080 cites W2156528952 @default.
• W2000302080 cites W2166556128 @default.
• W2000302080 cites W2336213711 @default.
• W2000302080 cites W2407337242 @default.
• W2000302080 doi "https://doi.org/10.1016/s0022-5347(05)68625-9" @default.
• W2000302080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10411086" @default.
• W2000302080 hasPublicationYear "1999" @default.
• W2000302080 type Work @default.
• W2000302080 sameAs 2000302080 @default.
• W2000302080 citedByCount "92" @default.
• W2000302080 countsByYear W20003020802013 @default.
• W2000302080 countsByYear W20003020802015 @default.
• W2000302080 countsByYear W20003020802016 @default.
• W2000302080 countsByYear W20003020802017 @default.
• W2000302080 countsByYear W20003020802018 @default.
• W2000302080 countsByYear W20003020802019 @default.
• W2000302080 countsByYear W20003020802021 @default.
• W2000302080 countsByYear W20003020802022 @default.
• W2000302080 countsByYear W20003020802023 @default.
• W2000302080 crossrefType "journal-article" @default.
• W2000302080 hasAuthorship W2000302080A5008028399 @default.
• W2000302080 hasAuthorship W2000302080A5010836672 @default.
• W2000302080 hasAuthorship W2000302080A5016349256 @default.
• W2000302080 hasAuthorship W2000302080A5039942289 @default.
• W2000302080 hasAuthorship W2000302080A5087442210 @default.
• W2000302080 hasAuthorship W2000302080A5089127172 @default.
• W2000302080 hasConcept C110121322 @default.
• W2000302080 hasConcept C120665830 @default.
• W2000302080 hasConcept C121332964 @default.
• W2000302080 hasConcept C126894567 @default.
• W2000302080 hasConcept C134306372 @default.
• W2000302080 hasConcept C202751555 @default.
• W2000302080 hasConcept C2777540882 @default.
• W2000302080 hasConcept C2779671804 @default.
• W2000302080 hasConcept C2779762690 @default.
• W2000302080 hasConcept C33923547 @default.
• W2000302080 hasConcept C55493867 @default.
• W2000302080 hasConcept C71924100 @default.
• W2000302080 hasConcept C86803240 @default.
• W2000302080 hasConcept C91881484 @default.
• W2000302080 hasConceptScore W2000302080C110121322 @default.
• W2000302080 hasConceptScore W2000302080C120665830 @default.
• W2000302080 hasConceptScore W2000302080C121332964 @default.
• W2000302080 hasConceptScore W2000302080C126894567 @default.
• W2000302080 hasConceptScore W2000302080C134306372 @default.
• W2000302080 hasConceptScore W2000302080C202751555 @default.
• W2000302080 hasConceptScore W2000302080C2777540882 @default.
• W2000302080 hasConceptScore W2000302080C2779671804 @default.
• W2000302080 hasConceptScore W2000302080C2779762690 @default.
• W2000302080 hasConceptScore W2000302080C33923547 @default.
• W2000302080 hasConceptScore W2000302080C55493867 @default.
• W2000302080 hasConceptScore W2000302080C71924100 @default.
• W2000302080 hasConceptScore W2000302080C86803240 @default.
• W2000302080 hasConceptScore W2000302080C91881484 @default.
• W2000302080 hasIssue "2" @default.
• W2000302080 hasLocation W20003020801 @default.
• W2000302080 hasLocation W20003020802 @default.
• W2000302080 hasOpenAccess W2000302080 @default.
• W2000302080 hasPrimaryLocation W20003020801 @default.
• W2000302080 hasRelatedWork W2000302080 @default.
• W2000302080 hasRelatedWork W2006456636 @default.
• W2000302080 hasRelatedWork W2012813457 @default.
• W2000302080 hasRelatedWork W2024922249 @default.
• W2000302080 hasRelatedWork W2025287384 @default.
• W2000302080 hasRelatedWork W2032793736 @default.
• W2000302080 hasRelatedWork W2047638469 @default.
• W2000302080 hasRelatedWork W2149322241 @default.
• W2000302080 hasRelatedWork W2726968058 @default.
• W2000302080 hasRelatedWork W2895409929 @default.
• W2000302080 hasVolume "162" @default.

• next